[The effects of noninvasive positive pressure ventilation treatment on plasma concentration of amino terminal-pro brain natriuretic peptide in congestive heart failure in patients with sleep apnea]

Plain-language guide to PMID 16780741 (2006): randomized controlled trial study of BNP (Nesiritide) in 12 patients, sleep apnea (obstructive).

Key Facts

PMID: 16780741
Journal: Zhonghua nei ke za zhi
Year: 2006
Study type: Randomized Controlled Trial
Authors: Zhao ZH et al. (9 authors)

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of BNP (Nesiritide) in the context of sleep apnea (obstructive), published as a randomized controlled trial.

Sleep apnea (SA) exerts adverse effects in patients with congestive heart failure (CHF).

Amino terminal-pro brain natriuretic peptide (NT-proBNP) is a useful target of CHF treatment.

The purpose of this study was to assess the short-term effect of positive pressure ventilation (PPV) on the plasma concentration of NT-proBNP in patients with both CHF and SA.

Who Took Part

The study group was 12 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

One hundred and five patients diagnosed with CHF participated in the study.

Seventy-seven patients were diagnosed as having SA.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Medical history was recorded, and Doppler echocardiography and overnight polysomnography were performed.

Patients with CHF and SA were randomly assigned to receive medical therapy alone (12 patients) or with the addition of PPV (14 patients) for 2 - 5 days.

What Was Measured

PubMed files the paper under topics including Enzyme-Linked Immunosorbent Assay, Heart Failure, Natriuretic Peptide, Brain, Peptide Fragments, Positive-Pressure Respiration and Sleep Apnea Syndromes.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 12 patients in people with sleep apnea (obstructive).

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (Zhonghua nei ke za zhi), a journal based in China.

More context: the BNP (Nesiritide) compound page, Sleep apnea (obstructive) research.

Our Notes on the Compound

BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.